Sutro Biopharma, Inc. (STRO)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO). Investors who purchased Sutro shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Sutro and certain of its officers and/or directors have violated federal securities laws.
On January 5, 2022, Sutro issued a press release “provid[ing] a clinical update from the Company's ongoing, fully enrolled, dose-expansion Phase 1 study of STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC), for patients with advanced ovarian cancer.” Although the Company stated that “[t]he interim data show that STRO-002 could potentially improve the lives of an underserved ovarian cancer patient population,” STRO-002’s impact on white blood cell count was sufficiently detrimental to call its benefit-to-risk ratio into question. On this news, Sutro’s stock price fell $4.06 per share, or 27.87%, to close at $10.51 per share on January 6, 2022.
If you are aware of any facts relating to this investigation or purchased Sutro shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.